Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Azelaic acid

Classification: B

Drug products: Finacea, Finacea®, Skinoren®

ATC code: D10AX03

Substances: azelaic acid

Summary

Controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical azelaic acid are lacking.
 
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of azelaic acid have been found.

Effects

Both male and female patients have been included in studies of the effect of azelaic acid in acne vulgaris or rosacea. However, relevant sex analysis has not been found. Analysis of published data from a small study on periorificial dermatitis (4 boys, 6 girls) did not show any sex difference in effect [1].

Adverse effects

No studies with a clinically relevant sex analysis regarding the dosing of azelaic acid have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2015-12-21

References

  1. Jansen T, Melnik BC, Schadendorf D. Steroid-induced periorificial dermatitis in children--clinical features and response to azelaic acid. Pediatr Dermatol. 2010;27:137-42. PubMed
  2. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Authors: Mia von Euler, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson